You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

KU-0059436

Showing 1 - 25 of 86
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin Trial in Belgium, Netherlands, United Kingdom

Active, not recruiting
  • Triple Negative Metastatic Breast Cancer
  • +3 more
  • KU-0059436 (AZD2281)(PARP inhibitor)
  • +3 more
  • Brussels, Belgium
  • +3 more
Dec 19, 2022

Ovarian Tumors, BRCA1 Protein, BRCA2 Protein Trial in Worldwide (KU-0059436 (AZD2281)(PARP inhibitor))

Active, not recruiting
  • Ovarian Neoplasms
  • +2 more
  • KU-0059436 (AZD2281)(PARP inhibitor)
  • Brussels, Belgium
  • +4 more
Dec 19, 2022

Breast Tumors Trial in Worldwide (KU-0059436 (AZD2281) (PARP inhibitor))

Completed
Has Results
  • Breast Neoplasms
  • KU-0059436 (AZD2281) (PARP inhibitor)
  • West Hollywood, California
  • +16 more
Jan 24, 2023

Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (Olaparib)

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 23, 2022

Laryngeal Cancer Stage II, Laryngeal Cancer Stage III, Carcinoma, Squamous Cell Trial in Amsterdam (radiotherapy, Olaparib)

Active, not recruiting
  • Laryngeal Cancer Stage II
  • +3 more
  • Amsterdam, Netherlands
    The Netherlands Cancer Institute
Sep 27, 2022

Squamous Cell Carcinoma of Head and Neck Trial in Chapel Hill, Charleston (biological, drug, radiation)

Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • Pembrolizumab
  • +3 more
  • Chapel Hill, North Carolina
  • +1 more
Oct 25, 2022

Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (Laboratory Biomarker Analysis, Olaparib,

Active, not recruiting
Has Results
  • Castration-Resistant Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Laboratory Biomarker Analysis
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 19, 2022

Prostate Cancer, Castration-resistant Prostate Cancer Trial in Washington, Baltimore (Olaparib, Vitamin C)

Not yet recruiting
  • Prostate Cancer
  • Castration-resistant Prostate Cancer
  • Washington, District of Columbia
  • +1 more
Aug 12, 2022

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Boston, Houston

Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 12, 2023

Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (biological, drug, other)

Recruiting
  • Biochemically Recurrent Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Durvalumab
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

Endometrial Serous Adenocarcinoma, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in United States

Recruiting
  • Endometrial Serous Adenocarcinoma
  • +2 more
  • Biopsy
  • +3 more
  • Phoenix, Arizona
  • +3 more
Feb 2, 2023

Pancreatic Cancer Trial (Pembrolizumab, Olaparib)

Not yet recruiting
  • Pancreatic Cancer
  • (no location specified)
Oct 21, 2021

Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer Trial in Baltimore (Olaparib)

Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • Baltimore, Maryland
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Mar 14, 2022

Ovarian Cancer Trial in Manchester (Olaparib, Cediranib, Platinum-based Chemotherapy)

Completed
  • Ovarian Cancer
  • Manchester, United Kingdom
    The Christie NHS Foundation Trust
Feb 4, 2022

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor Trial (procedure, biological,

Not yet recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +5 more
  • (no location specified)
Apr 8, 2023

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma

Not yet recruiting
  • Anatomic Stage III Breast Cancer AJCC v8
  • +3 more
  • (no location specified)
Jul 28, 2023

Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma Trial (Biopsy, Biospecimen Collection, Bone Marrow Aspiration and

Not yet recruiting
  • Recurrent Endometrial Carcinoma
  • Recurrent Ovarian Carcinoma
  • Biopsy
  • +5 more
  • (no location specified)
Sep 29, 2022

Locally Advanced Malignant Tumor, Inflammatory Breast Carcinoma, Triple-Negative Invasive Breast Carcinoma Trial in Amsterdam

Completed
  • Locally Advanced Malignant Neoplasm
  • +2 more
  • Amsterdam, Netherlands
    The Netherlands Cancer Institute
Aug 3, 2021

ARID1A Gene Mutation, ATM Gene Mutation, ATR Gene Mutation Trial in United States (Olaparib)

Recruiting
  • ARID1A Gene Mutation
  • +15 more
  • Scottsdale, Arizona
  • +4 more
Dec 13, 2022

Locally Advanced Unresectable Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8

Recruiting
  • Locally Advanced Pancreatic Carcinoma
  • +3 more
  • Biopsy
  • +5 more
  • Ann Arbor, Michigan
    University of Michigan Comprehensive Cancer Center EDDOP
Nov 30, 2022

Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8 Trial in New York

Not yet recruiting
  • Locally Advanced Leiomyosarcoma
  • +8 more
  • (no location specified)
Jul 6, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma Trial in Portland (procedure, drug,

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Metastatic Triple-Negative Breast Carcinoma
  • Biopsy
  • +6 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jul 29, 2022

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)

Active, not recruiting
Has Results
  • BRCA1 Gene Mutation
  • +5 more
  • Durvalumab
  • +3 more
  • Buffalo, New York
  • +1 more
Jan 20, 2023

Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma Trial in United States

Suspended
  • Recurrent Ovarian High Grade Serous Adenocarcinoma
  • Recurrent Platinum-Resistant Ovarian Carcinoma
  • Phoenix, Arizona
  • +8 more
Jul 26, 2022

Renal Cell Cancer Trial in Cambridge (Olaparib, Cediranib, Durvalumab)

Recruiting
  • Renal Cell Cancer
  • Cambridge, England, United Kingdom
    Addenbrooke's Hospital
May 21, 2021